Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-Al-NOTA-MATBBN is a radiopharmaceutical PET imaging agent developed by Wuxi No. 4 People's Hospital. It consists of a bombesin (BBN) analogue, MATBBN, which is conjugated to the chelator NOTA and labeled with fluorine-18 using the aluminum-fluoride (AlF) complexation method. MATBBN is a peptide designed to target the Gastrin-Releasing Peptide Receptor (GRPR), a G protein-coupled receptor that is frequently overexpressed in various cancers, including prostate and breast malignancies. By binding specifically to GRPR, the agent allows for the non-invasive visualization and localization of primary tumors and metastatic lesions via PET/CT imaging, facilitating the diagnosis, staging, and monitoring of GRPR-positive tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-Al-NOTA-MATBBN.